Literature DB >> 6722780

Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen.

R R Reddel, L C Murphy, R L Sutherland.   

Abstract

Cell proliferation kinetics during growth of an estrogen receptor-positive human breast carcinoma cell line, T-47D, was defined, and some factors which modify its response to tamoxifen were investigated in vitro. T-47D cells were estrogen responsive when grown in charcoal-stripped fetal calf serum, but the addition of 17 beta-estradiol did not fully restore the growth rate to that observed in the same concentration of fetal calf serum. Tamoxifen had both a low-dose, estrogen-reversible, growth-inhibitory effect and a high-dose, estrogen-irreversible, growth-inhibitory and cytotoxic effect on T-47D cells. Tamoxifen-induced growth inhibition was associated with a decrease in the percentage of S-phase cells and, to a lesser extent, G2-M-phase cells and an increase in G0-G1-phase cells. Plateau-phase cells were considerably less sensitive than were exponentially growing cells, and this was accompanied by a fall in unoccupied estrogen receptor content from 4407 +/- 655 (S.E.) sites/cell in exponentially growing cultures to 1420 +/- 315 sites/cell in plateau-phase cultures. T-47D cells were more sensitive to tamoxifen cytostasis when grown in fetal calf serum rather than charcoal-stripped fetal calf serum. However, with both types of growth medium, the sensitivity to tamoxifen was inversely related to the serum concentration, e.g., the 50%-inhibitory dose concentration increased 75-fold as the fetal calf serum concentration was increased from 0.25 to 10%. Addition of insulin to the culture medium had no effect on the growth rate, estrogen receptor content, or tamoxifen sensitivity of T-47D cells. These results illustrate that the conditions under which cells are cultured markedly affect their sensitivity to tamoxifen and highlight the need to specify these conditions when reporting effects of this drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6722780

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer.

Authors:  Angelika M Burger; Fathima Kona; Yutaka Amemiya; Yuguang Gao; Stephanie Bacopulos; Arun K Seth
Journal:  Open Cancer J       Date:  2010

2.  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

Authors:  E A Musgrove; C S Lee; R L Sutherland
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

3.  Variations in amplification and expression of the ornithine decarboxylase gene in human breast cancer cells.

Authors:  T Thomas; D T Kiang; O A Jänne; T J Thomas
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

Review 4.  Estrogen and progestin regulation of cell cycle progression.

Authors:  R L Sutherland; O W Prall; C K Watts; E A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

5.  Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells.

Authors:  R R Perry; Y Kang; B Greaves
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

6.  Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.

Authors:  E A Musgrove; J A Hamilton; C S Lee; K J Sweeney; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

7.  The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1.

Authors:  V Doucas; J P Brockes; M Yaniv; H de Thé; A Dejean
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

8.  Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.

Authors:  C K Watts; K J Sweeney; A Warlters; E A Musgrove; R L Sutherland
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Calcium antagonism by the antioestrogen tamoxifen.

Authors:  A Lipton; I D Morris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Unregulated expression of c-Jun or c-Fos proteins but not Jun D inhibits oestrogen receptor activity in human breast cancer derived cells.

Authors:  V Doucas; G Spyrou; M Yaniv
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.